Abstract
Hyperkalemia (HK), a serum potassium concentration above 5.0 mEq/L, is a potentially severe condition that may result in arrhythmias and sudden death. Renin-angiotensin-aldosterone system inhibitor (RAASi) treatment is a cornerstone in the management of chronic kidney disease (CKD) and heart failure (HF), but can also induce HK. Potassium binders are a key pillar in the treatment of HK, but routine use of conventional binders such as sodium polystyrene sulfonate (SPS) is hampered by questionable effectiveness and safety concerns.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
